The Post-Partisan Emporium

  Now Found in the Blood and in Organoids Please Disperse, There is nothing to see here. Anandamide Chakraborty had  the curiosity most of our regulators lack. Another Link He didn’t have to lift a pipette. Just had to know how to download data from the NCBI SRA and scan it for sequences that others don’t care to look for. He covers 3 Studies. One of the studies likely underrepresents the DNA as the study used a Qiagen  protocol to capture RNA  which selects against DNA. This would explain the high Spike to Vector sequencing ratio observed. In other words, the study favored capturing RNA and may have even used a DNaseI in that protocol. So its safe to assume the DNA loads, when measured with a kit designed to capture DNA would actually be much higher. The list is much longer than this but see his paper for the full list of patients. The second study also used this Qiagen kit. The 3rd study also used Qiagen kits. This one has some low numbers of SV40 reads in patients...

  The WHO: Building a Permanent Pandemic Market In the face of a potentially industry-ending slew of patent cliffs, Big Pharma has begun acquiring biotechnology companies to stave off collapse. To get these drugs to market, the industry is pursuing the only solution left for their dying model: a full takeover of the WHO to capture the global regulatory system. BY MAX JONES Big Pharma must soon confront an industry-wide hazard that reaches magnitudes far greater than the typical concerns of corporate profit margins and business politics. Through years of industry consolidation, it has essentially made itself “too big to fail.” Only now, the model which it once could never fail within — that is, the practice of obtaining patent exclusivity over drugs that are approved through clinical trials and regulations — has become obsolete, even impossible, under the current conditions of the industry.  In this new climate, the trials and regulations Big Pharma once successfully navigated ...